Fiducient Advisors LLC Sells 213 Shares of Amgen Inc. (NASDAQ:AMGN)

Fiducient Advisors LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,810 shares of the medical research company’s stock after selling 213 shares during the quarter. Fiducient Advisors LLC’s holdings in Amgen were worth $1,550,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new position in Amgen in the 2nd quarter worth approximately $26,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen during the 2nd quarter worth approximately $30,000. nVerses Capital LLC purchased a new stake in shares of Amgen during the 2nd quarter worth approximately $31,000. Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen during the 2nd quarter worth approximately $33,000. Finally, Matrix Trust Co purchased a new stake in shares of Amgen during the 3rd quarter worth approximately $36,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

AMGN opened at $315.54 on Thursday. Amgen Inc. has a 12-month low of $249.70 and a 12-month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The business’s fifty day simple moving average is $324.75 and its 200-day simple moving average is $314.78. The company has a market capitalization of $169.27 billion, a price-to-earnings ratio of 45.08, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the previous year, the company posted $5.00 EPS. Amgen’s quarterly revenue was up 20.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is currently 128.57%.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Sanford C. Bernstein initiated coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. TD Cowen upped their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Barclays upped their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $332.55.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.